QR Kod

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has exhibited promising clinical outcomes in treating relapsed/refractory (R/R) B-cell hematologic malignancies. Current studies have shown a close correlation between baseline tumor burden and therapeutic response in CAR-T cell therapy. However, the ro...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Ruimin Hong, Elaine Tan Su Yin, Linqin Wang, Xin Zhao, Linghui Zhou, Guangfa Wang, Mingming Zhang, Houli Zhao, Guoqing Wei, Yiyun Wang, Wenjun Wu, Yafei Zhang, Fang Ni, Yongxian Hu, He Huang, Kui Zhao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021-08-01
Seri Bilgileri:Frontiers in Oncology
Konular:
chimeric antigen receptor T-cell therapy
non-Hodgkin lymphoma
metabolic tumor burden
FDG PET/CT
prognosis
adverse effects
Online Erişim:https://www.frontiersin.org/articles/10.3389/fonc.2021.713577/full
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller